Influence of Bifid Triple Viable Enteric-coated Capsules on Liver Function and Inflammatory Factor in Pa-tients with Non-alcoholic Steatohepatitis / 中国药师

Objective:To discuss the influence of bifid triple viable enteric-coated capsules on liver function and inflammatory fac-tor in the patients with non-alcoholic steatohepatitis ( NASH) . Methods:Totally 70 cases of patients with NASH were selected and di-vided into the control group and the observation group at random. The patients in the two groups were all given routine hepatoprotective therapy. The patients in the observation group were additionally given 420mg bifid triple viable enteric-coated capsules, three times a day for 4 weeks. Except for bifid triple viable enteric-coated capsules, the patients in the control group were given the same medical treatment as that in the observation group. The changes of liver function index, serum high sensitivity C reaction protein ( hs-CRP) , IL-6 and IL-8 levels in the two groups before and after the medical treatment were observed and the security was compared. Results:After the 4-week medical treatment, ALT, GGT, serum hs-CRP, IL-6 and IL-8 levels in the two groups were obviously declined than those before the treatment (P0. 05). Conclusion:Bifid triple viable enteric-coated capsules in the treatment of NASH can obviously reduce the serum hs-CRP, IL-6 and IL-8 levels, inhibit the intrahepatic inflammation and immunologic injury, and improve the liver function index with high security.

Clinical Study on 180 Cases of Prophylactic Treatment with Bifid Triple Viable Enteric-coated Capsules for Preventing Children Diarrhea after Pneumonia / 中国药房

OBJECTIVE: To observe clinical efficacy of Bifid tripie viable enteric-coated capsules in the treatment of children diarrhea after pneumonia. METHODS: 360 cases of children pneumonia were randomly divided into two groups. Treatment group were treated with antibiotics and Bifid triple viable enteric-coated capsules in duration of hospital stay(n=180). Control group were treated with antibiotics only (n=180). The incidence and severity of diarrhea in two groups were observed at the 3rd, 5th, 7th of therapy. RESULTS: The incidence of diarrhea at the 3rd, 5th, 7th of therapy in treatment group were 10.00%,16.67% and 13.33%, in control group 36.67%, 43.33% and 50.00%, with statistically significance(P